We’re thrilled to launch our first clinical trial at Long COVID Labs, focused on testing a promising combination of two therapeutics: Pemgarda and Paxlovid. Both medications offer unique mechanisms that target SARS-CoV-2 differently, and this combination treatment could represent a new frontier in addressing persistent viral symptoms for Long COVID patients.
Pemgarda is a long-acting monoclonal antibody, specifically designed for individuals who struggle to produce their own antibodies—often those with compromised immune systems. With a half-life of 44 days, Pemgarda remains in the body longer than standard antibodies, providing sustained pressure on lingering viral particles. The drug binds directly to the virus, and potentially stimulates immune responses to help clear it from viral reservoirs in the body.
While it’s uncertain whether Pemgarda can cross the blood-brain barrier (BBB), some studies suggest that Long COVID patients experience increased BBB permeability, possibly allowing for a more effective clearing of viral particles in the brain—a key area of interest in managing cognitive symptoms.
Paxlovid brings a complementary mechanism to the mix. It’s a two-component antiviral that includes nirmatrelvir, which directly inhibits SARS-CoV-2’s main protease, and ritonavir, which slows the breakdown of nirmatrelvir. This combination slows viral replication by preventing the virus from assembling new viral particles, which may help reduce ongoing symptoms related to viral persistence.
Paxlovid, however, has numerous drug interactions, and some patients may need to pause certain medications while on it. Our trial will carefully monitor these interactions and prioritize safety.
Combining these two therapeutics aims to create a multi-layered approach to combat the virus, reducing the potential for resistance. Using drugs with different mechanisms of action is a strategy widely used in antiviral treatments to minimize the emergence of drug-resistant viral strains—a possible concern with SARS-CoV-2 in cases of Long COVID. This combination approach holds promise, as it addresses viral persistence from multiple angles, potentially leading to a more effective and lasting solution for patients.
Pemgarda’s availability as a long-acting monoclonal antibody in the U.S. and Paxlovid’s wide distribution make this combination a highly accessible option to start testing immediately. Pemgarda does require IV administration, which may limit access to those who can reach infusion centers. However, we are exploring partnerships with infusion clinics to expand availability.
Our trial joins a growing field of research exploring similar approaches, such as UCSF’s study on long-acting monoclonal antibody treatments for Long COVID. While other antibody candidates exist, Pemgarda’s FDA approval and track record make it the best candidate currently available for immediate testing.
While Pemgarda has shown promise, it does carry a 0.6% risk of anaphylaxis and requires administration in a clinical setting equipped for emergency response. Our trial will adhere to rigorous safety protocols, and all participants will be monitored closely to mitigate risks.
This trial marks an exciting step forward for Long COVID Labs and our mission to drive patient-centered, science-backed solutions. By exploring combination therapies like Pemgarda and Paxlovid, we hope to open new doors in understanding and treating the lingering effects of COVID-19. We’re optimistic about the potential of this combination therapy to make a meaningful impact on patients’ lives and will share updates as the trial progresses.
Stay tuned as we begin this journey and explore new possibilities in the fight against Long COVID.
